Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
DXG23V
|
||||
| Drug Name |
5-Bromo-4-[2-(1-methyl-piperidin-4-yl)-ethoxy]-6-[(spiro[2.5]oct-6-ylmethyl)-amino]-pyrimidine-2-carbonitrile
|
||||
| Synonyms |
CHEMBL526107
|
||||
| Indication | Discovery agent | Investigative | [1587926] | ||
| Formula |
C22H32BrN5O
|
||||
| Canonical SMILES |
CN1CCC(CCOc2nc(nc(NCC3CCC4(CC3)CC4)c2Br)C#N)CC1
|
||||
| InChI |
InChI=1S/C22H32BrN5O/c1-28-11-4-16(5-12-28)6-13-29-21-19(23)20(26-18(14-24)27-21)25-15-17-2-7-22(8-3-17)9-10-22/h16-17H,2-13,15H2,1H3,(H,25,26,27)
|
||||
| InChIKey |
HJUPPNTXGDFNAO-UHFFFAOYSA-N
|
||||
| Target and Pathway | |||||
| Target(s) | Cathepsin K | Target Info | [1587926] | ||
| Cathepsin L | Target Info | [1587926] | |||
| Reactome | Collagen degradation | ||||
| Degradation of the extracellular matrix | |||||
| Activation of Matrix Metalloproteinases | |||||
| Trafficking and processing of endosomal TLR | |||||
| MHC class II antigen presentationR-HSA-1236977:Endosomal/Vacuolar pathway | |||||
| Assembly of collagen fibrils and other multimeric structures | |||||
| MHC class II antigen presentation | |||||
| References | |||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.